Drug Trial Radar · NCT06455280
A Study of SIPLIZUMAB in AILD and LT Patients
Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Sep 11, 2024
Primary completion
Dec 31, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Elizabeth C. VernaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ITB-Med LLC
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT. Up to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses. All subjects will be followed in the study for 12 months post-LT.
Conditions
- Autoimmune Liver Disease
- Liver Transplant Disorder
- Autoimmune Hepatitis
- Primary Sclerosing Cholangitis
- End Stage Liver DIsease
- Cirrhosis, Liver
Interventions
SiplizumabDrug
Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serious infection in the first month post-transplant,Time frame: 1 Month post-transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.